You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美銀美林:升中生製藥(1177.HK)目標價至13.5港元 評級“買入”
格隆匯 11-08 11:27
美銀美林發表研究報告指,在內地舉行的會議上與中生製藥(1177.HK) 管理層會面,並繼續看好其創新管道進展及在商務發展的顯著投入。該行將其2021年每股基本盈利預測由0.29元人民幣升至0.3元人民幣,並將目標價由12港元升至13.5港元,重申評級 “買入”
報告指,公司擁有38種新化學實體(NCE)藥物及生物仿製藥處於臨牀階段,商務發展的努力亦引進更多晚期藥物;管理層預計2021年開始有一種或超過一種新藥獲批;安羅替尼(Anlotinib)銷售今年可接近30億元人民幣,明年將有約40%增長;公司預料其搶先上市的普米克令舒(Pulmicort)可於今年內獲批。該行相信Pulmicort將可成為重頭藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account